At the news
? NEUTRALIMPACT 2/10 25-NSE filed May 14, 2026 at 09:52 ET
Nasdaq filed a Form 25-NSE to remove Apellis Pharmaceuticals' common stock from listing and registration, effective May 14, 2026, following the completion of Biogen's acquisition. The delisting is a procedural step after the merger closed, with APLS stockholders receiving $41.00 per share plus CVRs.
- Form 25-NSE filed by Nasdaq Stock Market LLC to delist Apellis common stock under Rule 12d2-2(a)(3).
- Effectiveness date is May 14, 2026, the same day as the filing.
- Delisting follows Biogen's completed acquisition of Apellis for $41.00 per share plus CVRs.
- The security is removed from listing and registration due to the merger, not due to any operational failure.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access